SEC Company Response from ADEZA BIOMEDICAL CORP (CIK 0000902482) — Dec 6, 2004
ADEZA BIOMEDICAL CORP (CIK 0000902482)
Date: Dec. 6, 2004 · CIK: 0000902482 · Accession: 0000891618-04-001365
AI Filing Summary & Sentiment
File numbers found in text: 333-118012
Referenced dates: September 2, 2004
Letter
Securities and Exchange Commission Attn: Mr. Gregory S. Belliston Adeza Biomedical Corporation Registration Statement on Form S-1 Registration Number 333-118012
Dear Mr. Belliston:
Adeza Biomedical Corporation (the “Company”) hereby requests that the Commission take appropriate action to make the above-captioned Registration Statement effective at 2:30 PM Washington, D.C. local time on December 9, 2004, or as soon thereafter as possible.
The Company also requests that the Registration Statement on Form 8-A filed with the Commission on December 6, 2004 be declared effective concurrently with the above-captioned Registration Statement.
Pursuant to the comments of the Commission set forth in the letter dated September 2, 2004 in connection with the above-captioned Registration Statement, the Company acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Company may not assert this action as a defense in any proceedings initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any questions or comments regarding the foregoing, please contact me at (408) 745-0975 x126.
Sincerely,
Adeza Biomedical Corporation
Show Raw Text
CORRESP
1
filename1.htm
corresp
Adeza Biomedical Corporation
1240 Elko Drive
Sunnyvale, California 94089
December 6, 2004
BY FACSIMILE AND
EDGAR CORRESPONDENCE
The Secretary
Securities and Exchange Commission
450 Fifth Street, N.W. — Mailstop 3-9
Washington, D.C. 20549
Attn: Mr. Gregory S. Belliston
Adeza Biomedical Corporation
Registration Statement on Form S-1
Registration Number 333-118012
Dear Mr. Belliston:
Adeza Biomedical Corporation (the “Company”) hereby requests that the
Commission take appropriate action to make the above-captioned Registration
Statement effective at 2:30 PM Washington, D.C. local time on December 9, 2004,
or as soon thereafter as possible.
The Company also requests that the Registration Statement on Form 8-A
filed with the Commission on December 6, 2004 be declared effective
concurrently with the above-captioned Registration Statement.
Pursuant to the comments of the Commission set forth in the letter dated
September 2, 2004 in connection with the above-captioned Registration
Statement, the Company acknowledges that:
•
should the Commission or the Staff, acting pursuant to
delegated authority, declare the Registration Statement effective,
it does not foreclose the Commission from taking any action with
respect to the Registration Statement;
•
the action of the Commission or the Staff, acting pursuant to
delegated authority, in declaring the Registration Statement
effective, does not relieve the Company from its full responsibility
for the adequacy and accuracy of the disclosure in the Registration
Statement; and
•
the Company may not assert this action as a defense in any
proceedings initiated by the Commission or any person under the
federal securities laws of the United States.
Should you have any questions or comments regarding the foregoing, please
contact me at (408) 745-0975 x126.
Sincerely,
Adeza Biomedical Corporation
/s/ Mark Fischer-Colbrie
Mark Fischer-Colbrie
Chief Financial Officer
cc:
Mr. Emory V. Anderson (Adeza Biomedical Corporation)
Ms. Sarah O’Dowd (Heller Ehrman White & McAuliffe LLP)
Mr. Frederick W. Kanner (Dewey Ballantine LLP)